Management of HIV-associated tuberculosis in resource-limited settings: A state-of-the-art review

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Lawn, Stephen D ^a,b,c   Meintjes, Graeme ^b,c   McIlleron, Helen ^c   Harries, Anthony D ^a,d   Wood, Robin ^b,c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RIFAMPICIN; STAVUDINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ADVERSE DRUG REACTION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG MEGADOSE; HEALTH CARE POLICY; HIV ASSOCIATED TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LOW DRUG DOSE; MORTALITY; NONHUMAN; PATIENT COUNSELING; PRACTICE GUIDELINE; REVIEW; TUBERCULOSIS; CHEMOPROPHYLAXIS; DEVELOPING COUNTRY; EARLY DIAGNOSIS; METHODOLOGY; TIME; COMPLICATION; PROCEDURES;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CHEMOPREVENTION; DEVELOPING COUNTRIES; EARLY DIAGNOSIS; HIV INFECTIONS; HUMANS; TIME FACTORS; TUBERCULOSIS;

EID: 84895442786     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-253     Document Type: Review

References (152)

1. World Health Organization Global Tuberculosis Control Report 2012 2012, Geneva: World Health Organization, World Health Organization.
2. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009, 4:325-333. 10.1097/COH.0b013e32832c7d61, 19532072.
3. WHO/UNAIDS Global HIV/AIDS Response. Epidemic Update and Health Sector Progress Towards Universal Access. Progress report 2011 http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_UA_Report_en.pdf. 2011, WHO/UNAIDS.
4. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011, 378:57-72. 10.1016/S0140-6736(10)62173-3, 21420161.
5. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007, 196:S86-S107. 10.1086/518665, 17624830.
6. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013, 13:529-539. 10.1016/S1473-3099(13)70030-6, 23531391.
7. De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999, 3:457-465.
8. Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, Chimzizi R, Harrington M, Maher D, Williams BG, De Cock KM. The HIV-associated tuberculosis epidemic-when will we act?. Lancet 2010, 375:1906-1919. 10.1016/S0140-6736(10)60409-6, 20488516.
9. World Health Organization Interim Policy on Collaborative TB/HIV activities. Who/HTM/TB/2004.330 WHO/HTM/HIV/2004.1 2004, Geneva, Switzerland: WHO, World Health Organization.
10. World Health Organization WHO Policy on Collaborative TB/HIV Activities. Guidelines for National Programmes and Stakeholders 2012, Geneva, Switzerland: World Health Organization, World Health Organization.
11. World Health Organization Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach, June 2013 2013, Geneva, Switzerland: World Health Organization, World Health Organization.
12. World Health Organization Treatment of Tuberculosis: Guidelines - Fourth Edition 2010, Geneva, Switzerland: World Health Organization, World Health Organization.
13. World Health Organization Guidelines for the Management of Drug-Resistant Tuberculosis: 2011 Update 2011, Geneva, Switzerland: World Health Organization, World Health Organization.
14. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, Yeboue K, Honde M, Diomande M, Giordano C. The mortality and pathology of HIV infection in a west African city. AIDS 1993, 7:1569-1579. 10.1097/00002030-199312000-00005, 7904450.
15. Rana FS, Hawken MP, Mwachari C, Bhatt SM, Abdullah F, Ng'ang'a LW, Power C, Githui WA, Porter JD, Lucas SB. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr 2000, 24:23-29.
16. Ansari NA, Kombe AH, Kenyon TA, Hone NM, Tappero JW, Nyirenda ST, Binkin NJ, Lucas SB. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002, 6:55-63.
17. Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 2010, 7:e1000296. 10.1371/journal.pmed.1000296, 2889914, 20582324.
18. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009, 9:173-184. 10.1016/S1473-3099(09)70043-X, 19246021.
19. World Health Organization Improving the Diagnosis and Treatment of Smear-Negative Pulmonary and Extra-Pulmonary Tuberculosis among Adults and Adolescents. Recommendations for HIV-Prevalent and Resource-Constrained Settings. WHO/HTM/2007.379 & WHO/HIV/2007.1 2007, Geneva, Switzerland: World Health Organization, World Health Organization.
20. Holtz TH, Kabera G, Mthiyane T, Zingoni T, Nadesan S, Ross D, Allen J, Chideya S, Sunpath H, Rustomjee R. Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 2011, 11:533-540. 10.1016/S1473-3099(11)70057-3, 21514234.
21. Wilson D, Nachega J, Morroni C, Chaisson R, Maartens G. Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults. Int J Tuberc Lung Dis 2006, 10:31-38.
22. Lawn SD, Ayles H, Egwaga S, Williams B, Mukadi YD, Santos Filho ED, Godfrey-Faussett P, Granich RM, Harries AD. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis 2011, 15:287-295.
23. Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, Phanuphak P, Teeratakulpisarn N, Phanuphak N, Nguyen HD, Hoang TQ, Le HT, Varma J. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010, 362:707-716. 10.1056/NEJMoa0907488, 20181972.
24. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011, 204:S1159-S1167. 10.1093/infdis/jir411, 3192543, 21996698.
25. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, Grant AD, Churchyard GJ, Kimerling M, Shah S, Lawn SD, Wood R, Maartens G, Granich R, Date AA, Varma J. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011, 8:e1000391. 10.1371/journal.pmed.1000391, 3022524, 21267059.
26. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla A. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, 13:349-361. 10.1016/S1473-3099(13)70008-2, 23531388.
27. World Health Organization Roadmap for Rolling out Xpert Mtb/Rif for Rapid Diagnosis of TB and MDR-TB 2010, Geneva, Switzerland: World Health Organization, World Health Organization.
28. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 2012, 12:103. 10.1186/1471-2334-12-103, 3423001, 22536883.
29. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012, 12:201-209. 10.1016/S1473-3099(11)70251-1, 3315025, 22015305.
30. Peter JG, Theron G, Zyl-Smit R, Haripersad A, Mottay L, Kraus S, Binder A, Meldau R, Hardy A, Dheda K. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012, 40:1211-1220. 10.1183/09031936.00201711, 22362849.
31. Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, Boehme CC, Nicol M. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis 2013, 13:407. 10.1186/1471-2334-13-407, 24004840.
32. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS 2012, 26:1635-1643. 10.1097/QAD.0b013e3283553685, 22555166.
33. World Health Organization/UNAIDS Guidance on Provider-Initiated HIV Testing and Counselling in Health Facilities 2007, Geneva, Switzerland: WHO/UNIADS, World Health Organization/UNAIDS.
34. Kumar AM, Gupta D, Gupta RS, Satyanarayana S, Wilson S, Zachariah R, Lawn SD, Harries AD. HIV testing in people with presumptive tuberculosis: time for implementation. Lancet Respir Med 2013, 1:7-9.
35. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004, 364:1244-1251. 10.1016/S0140-6736(04)17141-9, 15464185.
36. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Lienhardt C, Burman W. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009, 6:e1000146. 10.1371/journal.pmed.1000146, 2736385, 19753109.
37. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, Vernon A, Lienhardt C. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009, 6:e1000150. 10.1371/journal.pmed.1000150, 2736403, 20101802.
38. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404. 10.1038/nrd4001, 23629506.
39. Jindani A, et al. A Multicentre Randomized Clinical Trial to Evaluate High-dose Rifapentine with a Quinolone for Treatment of Pulmonary TB: The RIFAQUIN Trial 2013, Atlanta, USA: Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections, Abstract #147LB.
40. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, Yapi A, Combe P, Tossou O, Roels TH, Lackritz EM, Coulibaly D, De Cock KM, Coulibaly IM, Greenberg AE. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999, 353:1469-1475. 10.1016/S0140-6736(99)03465-0, 10232312.
41. Zachariah R, Spielmann MP, Chinji C, Gomani P, Arendt V, Hargreaves NJ, Salaniponi FM, Harries AD. Voluntary counselling, HIV testing and adjunctive co-trimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003, 17:1053-1061. 10.1097/00002030-200305020-00015, 12700456.
42. Mwaungulu FB, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H, Harries AD, Glynn JR, Fine PE. Co-trimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004, 82:354-363. 2622842, 15298226.
43. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of co-trimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005, 19:163-168. 10.1097/00002030-200501280-00008, 15668541.
44. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 2008, 337:a257. 10.1136/bmj.a257, 2656923, 18617486.
45. Lowrance DW, Makombe S, Harries AD, Shiraishi RW, Hochgesang M, Berle-Grasse J, Libamba E, Schouten E, Ellerbrock T, Kamoto K. A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr 2008, 49:287-293. 10.1097/QAI.0b013e3181893ef0, 18845953.
46. World Health Organization The Global Plan to STOP TB 2011-2015 2010, Geneva, Switzerland: World Health Organization, World Health Organization.
47. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009, 30:685-699. 10.1016/j.ccm.2009.08.010, 2887494, 19925961.
48. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706. 10.1056/NEJMoa0905848, 3076221, 20181971.
49. hiv-druginteractions.org: Homepage [http://www.hiv-druginteractions.org], hiv-druginteractions.org: Homepage.
50. Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, Charalombous S, Churchyard G, Smith P, Maartens G. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009, 14:687-695. 3837290, 19704172.
51. Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, Shioda T, Khusmith S. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010, 7:8. 10.1186/1742-6405-7-8, 2859392, 20338069.
52. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 2011, 90:406-413. 10.1038/clpt.2011.129, 21814190.
53. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F, Adult AIDS, Clinical Trials Group A5221 Study Team Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS clinical trials group A5221 STRIDE study. Clin Infect Dis 2013, 57:586-593. 10.1093/cid/cit246, 23592830, Clinical Trials Group A5221 Study Team.
54. Boulle A, Van CG, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008, 300:530-539. 10.1001/jama.300.5.530, 18677025.
55. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491. 10.1056/NEJMoa1013607, 3327101, 22010914.
56. Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, Ciaffi L, Sobry A, Bastos R, Nunes E, Rouzioux C, Jani I, Calmy A, CARINEMO study group Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis 2013, 13:303-312. 10.1016/S1473-3099(13)70007-0, 23433590, CARINEMO study group.
57. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006, 20:1605-1612. 10.1097/01.aids.0000238406.93249.cd, 16868441.
58. Puls R, The ENCORE1 Study Group A daily dose of 400mg efavirenz (EFV) is non-inferior to the standard 600mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial. Abstract WELBB01. Kuala Lumpur, Malaysia: 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention 2013, IAS 2013, The ENCORE1 Study Group.
59. Federal Drug Administation (FDA) Sustiva labeling update/dosing adjustment with rifampin. [http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm294476.htm], Federal Drug Administation (FDA).
60. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 2011, 25:388-390. 10.1097/QAD.0b013e3283427e05, 21150552.
61. McIlleron HM, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry C, Smith P, Haas DW, Maartens G. Effects of rifampin-based antituberculosis therapy on plasma efavirenz oncentrations in children vary by CYP2B6 genotype. AIDS 2013, 27:1933-1940. 10.1097/QAD.0b013e328360dbb4, 24180002.
62. Ramachandran G, Ramesh K, Hemanth Kumar AK, Jagan I, Vasantha M, Padmapriyadarsini C, Narendran G, Rajasekaran S, Swaminathan S. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother 2009, 63:841-84. 10.1093/jac/dkp033, 19218571.
63. Leger P, Dillingham R, Beauharnais CA, Kashuba AD, Rezk NL, Fitzgerald DW, Pape JW, Haas DW. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis 2009, 200:955-964. 10.1086/605126, 2754599, 19659438.
64. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group Study A5095 Team Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004, 350:1850-1861. 10.1056/NEJMoa031772, 15115831, AIDS Clinical Trials Group Study A5095 Team.
65. Srikantiah P, Walusimbi MN, Kayanja HK, Mayanja-Kizza H, Mugerwa RD, Lin R, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS 2007, 21:1972-1974. 10.1097/QAD.0b013e32823ecf6e, 17721107.
66. Shao H, Crump J, Ramadhani H, Uiso L, Sendui-Nguyaine O, Kiwera R, et al. A randomised trial of early versus delayed fixed dose combination zidovudine/lamivudine/abacavir in patients coinfected with HIV and tuberculosis: early findings of the tuberculosis and immune reconstitution syndrome trial. Abstract #796. 2006, Denver, CO: Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections.
67. Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, Crowley S, Williams B, Ridzon R, Granich R, Gilks C. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?. Int J Tuberc Lung Dis 2012, 16:6-15. 10.5588/ijtld.10.0626, 21819645.
68. Veldkamp AI, Hoetelmans RM, Beijnen JH, Mulder JW, Meenhorst PL. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999, 29:1586. 10.1086/313548, 10585827.
69. la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, Koopmans PP, Hekster YA, Burger DM. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004, 48:1553-1560. 10.1128/AAC.48.5.1553-1560.2004, 400571, 15105105.
70. Rolla VC, Silva Vieira MA, Pereira PD, Lourenco MC, De Jesus CS, Goncalves MM, Ferreira FM, Werneck-Barroso E. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Investig 2006, 26:469-479. 10.2165/00044011-200626080-00005, 17163279.
71. Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother 2011, 55:3195-3200. 10.1128/AAC.01598-10, 3122443, 21537021.
72. L'homme RF, Nijland HM, Gras L, Aarnoutse RE, van Crevel R, Boeree M, Brinkman K, Prins JM, Juttmann JR, Burger DM. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009, 23:863-865.
73. Nijland HM, L'homme RF, Rongen GA, van Uden P, van Crevel R, Boeree MJ, Aarnoutse RE, Koopmans PP, Burger DM. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008, 22:931-935. 10.1097/QAD.0b013e3282faa71e, 18453852.
74. Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath H. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS ONE 2012, 7:e44793. 10.1371/journal.pone.0044793, 3460963, 23028623.
75. Decloedt EH, Maartens G, Smith P, Merry C, Bango F, McIlleron H. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PLoS ONE 2012, 7:e32173. 10.1371/journal.pone.0032173, 3296695, 22412856.
76. Sant'Anna FM, Velasque L, Costa MJ, Schmaltz CA, Morgado MG, Lourenco MC, Grinsztejn B, Rolla VC. Effectiveness of highly active antiretroviral therapy (HAART) used concomitantly with rifampicin in patients with tuberculosis and AIDS. Braz J Infect Dis 2009, 13:362-366.
77. Singh R, Marshall N, Smith CJ, Reynolds CJ, Breen RA, Bhagani S, Cropley I, Hopkins S, Swaden L, Johnson MA, Lipman MC. No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients. AIDS 2013, 27:481-484. 10.1097/QAD.0b013e32835a67fb, 23014518.
78. Matteelli A, Carvalho AC, Apostoli A, Tinelli C, Scudeller L, El Hamad I, Bonora S, Girardi E, Gori A, Mussini C. Completion Rate and Viro-Immunological Response to Combined TB/HIV Treatment: Results from the RIFART Study. [Abstract 854] 2013, Atlanta, GA: Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections.
79. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, Peloquin CA. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009, 49:1305-1311. 10.1086/606056, 19807276.
80. Khachi H, O'Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009, 64:871-873. 10.1093/jac/dkp263, 19628472.
81. Naiker S, Conolly C, Weisner L, Phillips D, Harries A, Lienhardt C, McIlleron H, Pym A. Pharmacokinetic Evaluation of Different Rifabutin Dosing Strategies in African TB Patients on Lopinavir/ritonavir-based ART [abstract 650] 2011, Boston, MA: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections.
82. Huy Dung N, Barrail-Tran A, Thi Ngoc Lan N, Hong Duc N, Thi Nguyet Thu N, Ngoc Lan N, Laureillard D, Thi Xuan Lien T, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Taburet A-M, Harries AD. Rifabutin Pharmacokinetics when Coadministered with Lopinavir/Ritonavir in HIV-infected Patients with Tuberculosis in Vietnam: results of ANRS12150b Cross-over Clinical Trial [abstract WEPE470]. 7th IAS Conference on HIV Pathogenesis and Treatment (Kuala Lumpur) 2013, Geneva, Switzerland: International AIDS Society.
83. Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009, 48:1471-1474. 10.1086/598336, 19368504.
84. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005, 40:1481-1491. 10.1086/429321, 15844071.
85. Department of Health and Human Services, Panel on antiretroviral guidelines for adults and adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf], Department of Health and Human Services, Panel on antiretroviral guidelines for adults and adolescents.
86. Moultrie H, McIlleron H, Sawry S, Kellermann T, Wiesner L, Kindra G, Gous H, Van Rie A. High Rate of Neutropenia in Young Children Receiving Concomitant Ribabutin and Lopinavir/Ritonavir [abstract 993] 2012, Seattle, WA: Program and abstracts of the 19th Conference on Retroviruses and Opportunistic Infections.
87. Ng J, Nada A, Freeman S, Chiu YL, Cohen D, Bernstein B, Awni W, Klein C. Pharmacokinetics of RIFABUTIN 150 mg TIW plus Lopinavir/Ritonavir (LPV/r) 400/100 mg Bid Administered in Healthy Adult Subjects (abstract O_21) 2009, Amsterdam, The Netherlands: 10th International Workshop on Clinical Pharmacology of HIV Therapy.
88. Sekar V, Lavreys L, de CT V, Berckmans C, Spinosa-Guzman S, Vangeneugden T, De Pauw M, Hoetelmans R. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 2010, 54:4440-4445. 10.1128/AAC.01749-09, 2944603, 20660678.
89. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, Mangin E, Marbury TC, Berg JK, Chodakewitz JA, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009, 53:2852-2856. 10.1128/AAC.01468-08, 2704654, 19433563.
90. Sauvageon H, Grinsztejn B, Arnold V, Veloso V, Vorsatz C, Pilotto JH, Grondin C, Chene G, Taburet A-M, Molina J-M. Pharmacokinetics of Two Doses of Raltegravir in Combination with Rifampin in HIV-TB co-infected Patients, an ANRS 12 180 Reflate TB sub-study [abstract 539] 2013, Atlanta, GA: Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections.
91. Mena A, Vazquez P, Castro A, Lopez S, Bello L, Pedreira JD. Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis. J Antimicrob Chemother 2011, 66:951-952. 10.1093/jac/dkq540, 21393209.
92. Grinsztejn B, De Castro N, Arnold V, Veloso V, Pilotto JH, Brites C, Vorsatz C, Grondin C, Chene G, Molina J-M. Efficacy and Safety of Raltegravir vs Efavirenz for the Treatment of HIV/TB patients: 48-week Results of the ANRS 12 180 Reflate TB Trial [abstract 853] 2013, Atlanta, GA: Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections.
93. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013, 62:21-27. 10.1097/QAI.0b013e318276cda9, 23075918.
94. Lawn SD, Torok ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 2011, 24:34-42. 10.1097/QCO.0b013e3283420f76, 3801096, 21150593.
95. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE, CAMELIA (ANRS 1295-CIPRA KH001) Study Team Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481. 10.1056/NEJMoa1013911, 22010913, CAMELIA (ANRS 1295-CIPRA KH001) Study Team.
96. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011, 365:1492-1501. 10.1056/NEJMoa1014181, 3233684, 22010915.
97. Török ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, Dung NT, Chau NV, Bang ND, Tien NA, Minh NH, Hien NQ, Thai PV, Dong DT, Anh do TT, Thoa NT, Hai NN, Lan NN, Lan NT, Quy HT, Dung NH, Hien TT, Chinh NT, Simmons CP, de Jong M, Wolbers M, Farrar JJ. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011, 52:1374-1383. 10.1093/cid/cir230, 21596680.
98. Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, Thawornwan U, Suntisuklappon B, Nilkamhang S, Sungkanuparph S. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 2012, 60:377-383. 10.1097/QAI.0b013e31825b5e06, 22592586.
99. Marais S, Meintjes G, Pepper DJ, Dodd LE, Schutz C, Ismail Z, Wilkinson KA, Wilkinson RJ. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 2013, 56:450-460. 10.1093/cid/cis899, 3540040, 23097584.
100. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952. 10.1164/rccm.200510-1666ST, 17021358, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee.
101. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004, 170:229-238. 315530, 14734438.
102. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM, 2NN Study team Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263. 10.1016/S0140-6736(04)15997-7, 15094269, 2NN Study team.
103. Lorent N, Sebatunzi O, Mukeshimana G, den EJ V, Clerinx J. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. PLoS ONE 2011, 6:e19566. 10.1371/journal.pone.0019566, 3097195, 21611117.
104. Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, Yamuah L, Feleke B, Aseffa A. Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS ONE 2008, 3:e1809. 10.1371/journal.pone.0001809, 2265547, 18350147.
105. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, Ballinger J, Swaden L, Johnson MA, Cropley I, Lipman MC. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006, 61:791-794. 10.1136/thx.2006.058867, 2117099, 16844730.
106. Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, Davis H, Boulos R, Quinn TC, Halsey NA. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996, 154:1034-1038. 10.1164/ajrccm.154.4.8887603, 8887603.
107. Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, Portaels F, Willame JC, Mandala JK, Kaboto M, Ryder RW, Roscigno G, Piot P. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995, 332:779-784. 10.1056/NEJM199503233321204, 7862181.
108. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009, 20:339-345. 10.1258/ijsa.2008.008361, 19386972.
109. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007, 21:1301-1308. 10.1097/QAD.0b013e32814e6b08, 17545706.
110. Shipton LK, Wester CW, Stock S, Ndwapi N, Gaolathe T, Thior I, Avalos A, Moffat HJ, Mboya JJ, Widenfelt E, Essex M, Hughes MD, Shapiro RL. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis 2009, 13:360-366. 2696339, 19275797.
111. Kalyesubula R, Kagimu M, Opio KC, Kiguba R, Semitala CF, Schlech WF, Katabira ET. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci 2011, 11:16-23. 3092323, 21572852.
112. Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, Sreenivas V, Singh S. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010, 50:833-839. 10.1086/650576, 20156055.
113. Schutz C, Ismail Z, Proxenos CJ, Marais S, Burton R, Kenyon C, Maartens G, Wilkinson RJ, Meintjes G. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. S Afr Med J 2012, 102:506-511. 3605782, 22668951.
114. Lehloenya RJ, Dheda K. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Rev Anti Infect Ther 2012, 10:475-486. 10.1586/eri.12.13, 22512756.
115. Toma E, Fournier S. Adverse reactions to co-trimoxazole in HIV infection. Lancet 1991, 338:954.
116. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001, 15:1843-1848. 10.1097/00002030-200109280-00014, 11579247.
117. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003, 167:1472-1477. 10.1164/rccm.200206-626OC, 12569078.
118. Lehloenya RJ, Todd G, Badri M, Dheda K. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. Int J Tuberc Lung Dis 2011, 15:1649-1657. 10.5588/ijtld.10.0698, 22118173.
119. Kenyon C, Wearne N, Burton R, Meintjes G. The risks of concurrent treatment with tenofovir and aminoglycosides in patients with hiv-associated tuberculosis. South Afr J HIV Med 2011, 12:43-45. 3118283, 21695064.
120. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, van der Loeff MS, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R, International Network for the Study of HIV-associated IRIS Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523. 10.1016/S1473-3099(08)70184-1, 2804035, 18652998, International Network for the Study of HIV-associated IRIS.
121. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005, 5:361-373. 10.1016/S1473-3099(05)70140-7, 15919622.
122. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007, 21:335-341. 10.1097/QAD.0b013e328011efac, 17255740.
123. Breen RA, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, Lipman MC. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004, 59:704-707. 10.1136/thx.2003.019224, 1747098, 15282393.
124. Burman W, Weis S, Vernon A, Khan A, Benator D, Jones B, Silva C, King B, LaHart C, Mangura B, Weiner M, El-Sadr W. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007, 11:1282-1289.
125. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005, 10:417-422.
126. Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, Bamber S, Gengiah S, El-Sadr WM, Friedland G, Abdool Karim S. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012, 157:313-324. 10.7326/0003-4819-157-5-201209040-00004, 3534856, 22944873.
127. Meintjes G, Rangaka MX, Maartens G, Rebe K, Morroni C, Pepper DJ, Wilkinson KA, Wilkinson RJ. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009, 48:667-676. 10.1086/596764, 2737129, 19191655.
128. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and " unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008, 177:680-685. 10.1164/rccm.200709-1311PP, 2277208, 18202347.
129. Pepper DJ, Marais S, Maartens G, Rebe K, Morroni C, Rangaka MX, Oni T, Wilkinson RJ, Meintjes G. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009, 48:e96-e107. 10.1086/598988, 19405867.
130. Agarwal U, Kumar A, Behera D, French MA, Price P. Tuberculosis associated immune reconstitution inflammatory syndrome in patients infected with HIV: meningitis a potentially life threatening manifestation. AIDS Res Ther 2012, 9:17. 10.1186/1742-6405-9-17, 3427137, 22620862.
131. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:251-261. 10.1016/S1473-3099(10)70026-8, 20334848.
132. Olalla J, Pulido F, Rubio R, Costa MA, Monsalvo R, Palenque E, Costa JR, Del PA. Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease. Int J Tuberc Lung Dis 2002, 6:71-75.
133. Breton G, Bourgarit A, Pavy S, Bonnet D, Martinez V, Duval X, Longuet P, Abgrall S, Simon A, Leport C. Treatment for tuberculosis-associated immune reconstitution inflammatory syndrome in 34 HIV-infected patients. Int J Tuberc Lung Dis 2012, 16:1365-1370. 10.5588/ijtld.11.0693, 23107635.
134. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, Oni T, Maartens G. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010, 24:2381-2390. 2940061, 20808204.
135. Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011, 9:415-430. 10.1586/eri.11.21, 3252684, 21504399.
136. Meintjes G, Schutz C. Preventing Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone (Pred-ART). [http://clinicaltrials.gov/show/NCT01924286].
137. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004, 351:1741-1751. 10.1056/NEJMoa040573, 15496623.
138. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010, 10:482-496. 10.1016/j.coph.2010.04.001, 20427238.
139. Conesa-Botella A, Meintjes G, Coussens AK, van der Plas H, Goliath R, Schutz C, Moreno-Reyes R, Mehta M, Martineau AR, Wilkinson RJ, Colebunders R, Wilkinson KA. Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. Clin Infect Dis 2012, 55:1004-1011. 10.1093/cid/cis577, 3436923, 22715179.
140. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006, 6:358-370. 10.1038/nri1839, 3842637, 16639429.
141. Sun HY, Singh N. Potential role of statins for the management of immune reconstitution syndrome. Med Hypotheses 2010,
142. Sierra-Madero J, Tierney A, Rassool M, Azzoni L, Sereti I, Andrade J, Mosqueda-Gomes L, Sanne I, Lederman M, CADRIS Study Team Efficacy and Safety of Maraviroc to Prevent Immune Reconstitution Inflammatory Syndrome in High-risk Subjects Initiating ART: 24-Week Results of a Randomized, Placebo-controlled Trial 2013, Altanta, GA: Program and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections, CADRIS Study Team.
143. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 2007, 196:S482-S490. 10.1086/521121, 18181698.
144. World Health Organization Molecular line probe assays for rapid screning of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement June 2008. [http://www.who.int/tb/features_archive/policy_statement.pdf] 2008, World Health Organization.
145. Kalokhe AS, Shafiq M, Lee JC, Ray SM, Wang YF, Metchock B, Anderson AM, Nguyen ML. Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing. Am J Med Sci 2013, 345:143-148. 10.1097/MAJ.0b013e31825d32c6, 22885627.
146. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9:e1001300. 10.1371/journal.pmed.1001300, 3429397, 22952439.
147. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161. 10.1016/S1473-3099(09)70041-6, 19246019.
148. Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, Saranchuk P, Da Silva E, Khan S, Paryani R, Udwadia Z, Migliori GB, Sotgiu G, Reid T. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai. India. PLoS ONE 2012, 7:e40781.
149. Coyne KM, Pozniak AL, Lamorde M, Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009, 23:437-446. 10.1097/QAD.0b013e328326ca50, 19256042.
150. Brust JC, Shah NS, van der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, Friedland GH, Gandhi NR. Adverse events in an integrated, home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr 2012,
151. Arentz M, Pavlinac P, Kimerling ME, Horne DJ, Falzon D, Schunemann HJ, Royce S, Dheda K, Walson JL. Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS ONE 2012, 7:e47370. 10.1371/journal.pone.0047370, 3489892, 23144818.
152. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:684-692. 10.1164/rccm.201001-0077OC, 20442432.